Clinical features of DH lymphomas
| Study . | No. of DH/total study size (%) . | DHs with prior history of indolent lymphoma, n/N (%)* . | Age, median (range) . | Stage III/IV, n/N (%) . | LDH > ULN, n/N (%) . | BM+, n/N (%) . | CNS+, n/N (%) . | >1E site, n/N (%) . | IPI HI-H, n/N (%) . |
|---|---|---|---|---|---|---|---|---|---|
| Bertrand et al40 2007 | 10/17 (59) | 1/10 (10) | 58 (45-81) | 7/10 (70) | NA† | NA | NA | NA | 5/9 (56)‡ |
| Johnson et al15 2009 | 54/54 (100) | 20/54 (46) | 62 (24-93) | 41/54 (76) | 27/54 (50) | 32/45 (71)§ | NA | 19/54 (35) | 38/54 (70)‖ |
| Kanungo et al13 2006 | 14/14 (100) | None | 55 (29-72) | NA | 13/14 (93) | 11/14 (79) | 3/14 (21) | 8/14 (57)¶ | NA |
| Le Gouill et al10 2007 | 16/16 (100) | 4/16 (25) | 61 (36-73) | 16/16 (100) | 16/16 (100) | 15/16 (94) | 8/16 (50) | 14/16 (88) | 13/16 (81) |
| Macpherson et al112 1999# | 15/39 (38) | 6/13 (46) | 65** | 12/13 (92) | 8/10†† (80) | 9/13 (69) | NA | 8/13 (62) | 9/10 (90)†† |
| Niitsu et al12 2009 | 19/19 (100) | None | 61 (29-79) | 19/19 (100) | 19/19 (100) | 16/19 (84) | 4/19 (21) | 12/19 (63) | 17/19 (89) |
| Snuderl et al14 2010‡‡ | 20/20 (100) | 3/20§§ (15) | 64 (32-91) | 18/19 (95) | 18/18 (100) | 10/17 (59) | 5/11 (45) | 6/20 (30)¶ | 17/20 (85) |
| Tomita et al11 2009‖‖ | 27/27 (100) | 4/23 (17) | 51 (36-79) | 22/23 (96) | 25/27 (93) | 15/23 (65) | 2/23 (9) | 15/23 (65) | 20/23 (87) |
| Study . | No. of DH/total study size (%) . | DHs with prior history of indolent lymphoma, n/N (%)* . | Age, median (range) . | Stage III/IV, n/N (%) . | LDH > ULN, n/N (%) . | BM+, n/N (%) . | CNS+, n/N (%) . | >1E site, n/N (%) . | IPI HI-H, n/N (%) . |
|---|---|---|---|---|---|---|---|---|---|
| Bertrand et al40 2007 | 10/17 (59) | 1/10 (10) | 58 (45-81) | 7/10 (70) | NA† | NA | NA | NA | 5/9 (56)‡ |
| Johnson et al15 2009 | 54/54 (100) | 20/54 (46) | 62 (24-93) | 41/54 (76) | 27/54 (50) | 32/45 (71)§ | NA | 19/54 (35) | 38/54 (70)‖ |
| Kanungo et al13 2006 | 14/14 (100) | None | 55 (29-72) | NA | 13/14 (93) | 11/14 (79) | 3/14 (21) | 8/14 (57)¶ | NA |
| Le Gouill et al10 2007 | 16/16 (100) | 4/16 (25) | 61 (36-73) | 16/16 (100) | 16/16 (100) | 15/16 (94) | 8/16 (50) | 14/16 (88) | 13/16 (81) |
| Macpherson et al112 1999# | 15/39 (38) | 6/13 (46) | 65** | 12/13 (92) | 8/10†† (80) | 9/13 (69) | NA | 8/13 (62) | 9/10 (90)†† |
| Niitsu et al12 2009 | 19/19 (100) | None | 61 (29-79) | 19/19 (100) | 19/19 (100) | 16/19 (84) | 4/19 (21) | 12/19 (63) | 17/19 (89) |
| Snuderl et al14 2010‡‡ | 20/20 (100) | 3/20§§ (15) | 64 (32-91) | 18/19 (95) | 18/18 (100) | 10/17 (59) | 5/11 (45) | 6/20 (30)¶ | 17/20 (85) |
| Tomita et al11 2009‖‖ | 27/27 (100) | 4/23 (17) | 51 (36-79) | 22/23 (96) | 25/27 (93) | 15/23 (65) | 2/23 (9) | 15/23 (65) | 20/23 (87) |
LDH indicates lactate dehydrogenase; ULN, upper limit of normal; BM+, bone marrow involvement; CNS+, central nervous system involvement; >1E, involvement of >1 extranodal site; IPI, International Prognostic Index; HI, high-intermediate (IPI score 3); H, high (IPI score 4 or 5); and NA, no specific information available.
Follicular lymphoma, n = 29; chronic lymphocytic leukemia, n = 1; and low-grade lymphoma (not otherwise specified), n = 8.
LDH values available but no ULN provided.
IPI not available in 1 case.
Not available in 9 cases.
IPI score at least low-intermediate (IPI score 2 or higher). No specific information about distribution between patients in low-intermediate and HI groups available.
Involvement of > 1 extranodal site calculation was based on data presented in the original paper.
For the clinical parameters only information for BCL2+/MYC+DH cases (n = 13) was available; for BCL6+/MYC+ DH (n = 2) cases no specific information was available.
No age-range for DHs available.
LDH and IPI not available in all cases.
For some cases not all clinical parameters were available.
Three cases with confirmed preexisting follicular lymphoma.
Lymphoma type DH (n = 23), leukemia type DH (n = 4).